Zephyrnet Logo

Sudarshan Pharma Initial Public Offering Subscription Status – Subscription Now Available

Date:

The Sudarshan Pharma Initial Public Offering (IPO) is now available for subscription. This is a great opportunity for investors to get in on the ground floor of this promising pharmaceutical company. Sudarshan Pharma is a leading manufacturer of generic drugs and has been in business for over 25 years. The company has a strong presence in the Indian market and is looking to expand its reach to other countries.

The IPO is open for subscription from April 19th to April 23rd, 2021. The offer price is Rs. 575 per share and the minimum application amount is Rs. 5,000. The issue size is Rs. 1,250 crore and the company has set aside 10% of the issue size for retail investors. The issue will be listed on the National Stock Exchange and Bombay Stock Exchange.

The company has a strong financial position and has been profitable for the last three years. It has a healthy balance sheet with no debt and a strong cash flow. The company has also been investing heavily in research and development to develop new products and expand its product portfolio.

The company’s management team consists of experienced professionals with extensive experience in the pharmaceutical industry. The team has a track record of delivering consistent performance and has been able to maintain a high level of customer satisfaction.

Investors should consider the company’s financials, management team, and product portfolio before investing in the IPO. The company’s track record of delivering consistent performance and its strong financial position make it an attractive investment opportunity. Investors should also consider the risks associated with investing in IPOs before making any decisions.

Overall, the Sudarshan Pharma Initial Public Offering is an attractive investment opportunity for investors looking to get in on the ground floor of a promising pharmaceutical company. Investors should consider the company’s financials, management team, and product portfolio before investing in the IPO.

spot_img

Latest Intelligence

spot_img